ETF Objective
The Fund seeks to replicate the price and yield performance of the Market Vectors US Listed Biotech 25 Index. The Index is comprised of common stocks and depository receipts of US exchange-listed companies in biotechnology sector.
Sector Breakdown
| Health Care | 94.93% | |
| Technology | 4.95% |
Geographic Exposure
| United States | 84.47% | |
| Germany | 4.76% | |
| China | 3.65% | |
| Ireland | 3.23% | |
| Netherlands | 2.70% | |
| Switzerland | 1.19% |
Top 10 Holdings
| Symbol | Company Name | % Of Assets |
|---|---|---|
| AMGN | Amgen Inc ORD | 13.00% |
| MRNA | Moderna Inc ORD | 7.62% |
| VRTX | Vertex Pharmaceuticals Inc ORD | 6.76% |
| GILD | Gilead Sciences Inc ORD | 6.60% |
| REGN | Regeneron Pharmaceuticals Inc ORD | 6.60% |
| ILMN | Illumina Inc ORD | 5.22% |
| IQV | IQVIA Holdings Inc ORD | 4.95% |
| BNTX | BioNTech SE DR | 4.76% |
| BIIB | Biogen Inc ORD | 4.40% |
| TECH | Bio-Techne Corp ORD | 4.24% |
ETF Overview
| Sponsor | Van Eck |
|---|---|
| iNav Ticker | BJW9 |
| Inception Date | 12/20/2011 |
| Name | VanEck:Biotech |
|---|---|
| CUSIP | 92189F726 |
| Prospectus Date | 02/01/2022 |
ETF Characteristics
| Market Capitalization | 51.90 B |
|---|---|
| Total Net Assets | 439.00 |
| Management Fee | 0.32% |
| Administration Fee | 0.00% |
| Asset Class | Equity |
| Sub Asset Class | Health/Biotechnology Funds |
| Number Of Holdings | 26 |
| Expense Ratio | 0.35 |
| Dividend | n/a |
| Dividend Frequency | Annually |
Latest News
2 dirt-cheap big pharma stocks poised to beat biotech's bad rap
May 2, 2016 11:06 AM EDT
Great Rotation? ETFs Encounter a Different Kind of Shift
Apr 12, 2014 6:00 AM EDT
How to Know if You Are Really a 'Value' Investor
Dec 11, 2013 11:32 AM EST
2 ETF Sectors Profiting From Individual Stock Trends
Dec 17, 2012 11:04 AM EST